In a major step for neurological healthcare, global pharmaceutical giant Eli Lilly officially launched its breakthrough Alzheimer’s treatment, Lormalzi, in India this week. The drug, which targets the root causes of memory loss rather than just symptoms, will be available to patients starting May 2026. This introduction comes at a critical time as India’s dementia-affected population is projected to reach nearly 19 million by 2036. The therapy is priced at approximately ₹91,688 per vial, making it one of the first advanced treatments for the disease to be commercially accessible in the Indian market.
Unlike traditional medications that only manage the confusion and memory lapses associated with Alzheimer’s, Lormalzi (known scientifically as donanemab) is a “disease-modifying” therapy. It works by identifying and removing amyloid plaques—sticky protein clumps that build up in the brain and disrupt communication between nerve cells.
By clearing these plaques, the drug can significantly slow down the mental decline in patients who are in the early stages of the disease, specifically those with mild cognitive impairment or mild dementia.
The drug is administered once every four weeks via an intravenous (IV) infusion. A key highlight for many families is that this is not a lifelong treatment. Clinical protocols suggest that once the amyloid plaques are sufficiently cleared from the brain, the treatment can be stopped, typically after a period of 18 months.
Eli Lilly has received official marketing authorization from India’s Central Drugs Standard Control Organization (CDSCO). To ensure broader reach despite the high cost, the company has announced plans for an “alternative access program” to assist eligible patients who may struggle with the monthly price tag.
Medical experts have welcomed the move, noting that India currently has over 8.8 million people living with dementia. As life expectancy increases across the country, the economic and emotional burden on caregivers has become a national concern. This launch represents a shift in Indian medicine from simple caregiving to active intervention, offering a new sense of hope for millions of aging citizens and their families.
